Based on these results, belantamab-mafodotin has been approved in monotherapy for R/R MM patients already exposed to four prior lines of therapy, including proteasome inhibitors, anti-CD38 MoAbs, and IMiDs. This evidence concerns the gene CD38 and Miyoshi myopathy.